rs759876319
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000527.5(LDLR):c.1634G>A(p.Gly545Glu) variant causes a missense change. The variant allele was found at a frequency of 0.00000753 in 1,461,612 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G545R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.1634G>A | p.Gly545Glu | missense_variant | 11/18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.1634G>A | p.Gly545Glu | missense_variant | 11/18 | 1 | NM_000527.5 | ENSP00000454071 | P3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251474Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135916
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1461612Hom.: 0 Cov.: 30 AF XY: 0.0000110 AC XY: 8AN XY: 727094
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial hypercholesterolemia Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 20, 2024 | Variant summary: LDLR c.1634G>A (p.Gly545Glu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251474 control chromosomes. c.1634G>A has been reported in the literature in multiple individuals affected with Familial Hypercholesterolemia (Trinder_2020, Ahmed_2013) and observed to segregate with disease. These data indicate that the variant is very likely to be associated with disease. Additionally, other missense variants affecting the same codon (Gly545Trp, Gly545Arg) have been classified on the pathogenic spectrum in ClinVar. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 23535506, 33079599). ClinVar contains an entry for this variant (Variation ID: 251945). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 29, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 545 of the LDLR protein (p.Gly545Glu). This variant is present in population databases (rs759876319, gnomAD 0.006%). This missense change has been observed in individual(s) with familial hypercholesterolemia (PMID: 23535506). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 251945). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. This variant disrupts the p.Gly545 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26020417, 26343872; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Gly545Glu variant in LDLR has been reported in 1 Pakistani family with familial hypercholesterolemia, segregated with disease in at least 8 affected relatives from 1 family (PMID: 23535506), and has been identified in 0.006533% (2/30616) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs759876319). This variant has also been reported in ClinVar (VariationID: 251945) as pathogenic by Integrated Genetics and as likely pathogenic by the British Heart Foundation and Fulgent Genetics. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional pathogenic variant, resulting in a different amino acid change at the same position, p.Gly545Trp, have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 25741862, 29874871, 17765246;Variation ID: 251944). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PP1_strong, PM5, PP3 (Richards 2015). - |
Hypercholesterolemia, familial, 1 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | literature only | LDLR-LOVD, British Heart Foundation | Mar 25, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Homozygous familial hypercholesterolemia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 04, 2019 | The p.Gly545Glu variant in LDLR has been reported in 1 large Pakistani family with familial hypercholesterolemia (FH) and segregated with disease in 3 homozygous and 17 heterozygous affected relatives (Ahmed 2013). Overall mean total cholesterol levels were significantly higher in those family members with the p.Gly545Glu variant compared to those without. Additionally, total cholesterol levels in homozygotes was significantly higher than heterozygotes. This variant has also been reported by other clinical laboratories in ClinVar (Variation ID: 251945) and has been identified in 0.007% (2/30616) of South Asian chromosomes by gnomAD (http://gnomad.broadinstitute.org). This frequency is low enough to be consistent with the frequency of FH in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant FH. ACMG/AMP Criteria applied: PP1_Strong, PM2. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at